NCT01327521 is a Phase 3 clinical trial of CyberKnife in Carcinoma, Hepatocellular, sponsored by Albert Koong.

Who is sponsoring NCT01327521?

NCT01327521 is sponsored by Albert Koong.

What drugs are being tested in NCT01327521?

Interventions in NCT01327521: CyberKnife, TACE, CT Contrast, doxorubicin, Epirubicin, 5-fluorouracil, Mitomycin C, Gemcitabine, Cisplatin, SMANCS.

What condition does NCT01327521 study?

NCT01327521 studies Carcinoma, Hepatocellular.

Is NCT01327521 still recruiting?

NCT01327521 is currently withdrawn. Last updated 7 June 2012.

Last reviewed 2012-06-07 · How we verify

NCT01327521

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

International Randomized Study of Transarterial Chemoembolization Versus CyberKnife for Recurrent Hepatocellular Carcinoma

Withdrawn Phase 3 Last updated 7 June 2012

What this trial tests

Phase 3 trial testing CyberKnife in Carcinoma, Hepatocellular. Withdrawn.

Timeline

1 February 2011

Primary endpoint
1 February 2014

Quick facts

Lead sponsor	Albert Koong
Phase	Phase 3
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Start date	1 February 2011
Primary completion	1 February 2014
Sites	1 location across United States

Drugs / interventions tested

CyberKnife
TACE
CT Contrast — full drug profile →
doxorubicin (doxorubicin) — full drug profile →
Epirubicin (EPIRUBICIN) — full drug profile →
5-fluorouracil
Mitomycin C
Gemcitabine (gemcitabine) — full drug profile →
Cisplatin (cisplatin) — full drug profile →
SMANCS

Conditions studied

Carcinoma, Hepatocellular — all drugs for Carcinoma, Hepatocellular →

Sponsor

Albert Koong — full company profile →

Who can join

18 and older, any sex, with Carcinoma, Hepatocellular. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Freedom from local progression at 6 months and 12 months
Time frame: 6 months and 12 months

Sponsor's own description

Primary Objective: To compare the efficacy of TACE vs. CyberKnife SBRT in the treatment of locally recurrent HCC after initial TACE. Secondary Objectives: 1. To determine the progression-free survival of TACE vs. CyberKnife SBRT 2. To determine the overall survival of TACE vs. CyberKnife SBRT for locally recurrent HCC 3. To determine the toxicities associated with TACE or CyberKnife SBRT for the treatment of recurrent HCC.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Trial watch: Chemotherapy with immunogenic cell death inducers.
Vacchelli E, Galluzzi L, Fridman WH, Galon J, et al · · 2012 · cited 98× · PMID 22720239 · DOI 10.4161/onci.1.2.19026
Development of regional chemotherapies: feasibility, safety and efficacy in clinical use and preclinical studies.
Cai S, Bagby TR, Forrest ML. · · 2011 · cited 7× · PMID 22229080 · DOI 10.4155/tde.11.112

Verify or expand the search:

Other trials of CyberKnife

Trials testing the same drug.

NCT01165346 — Stereotaxic Irradiation of Hepatocellular Carcinoma · Phase 2 · completed

Other recruiting trials for Carcinoma, Hepatocellular

Currently open trials in the same condition.

NCT07010497 — A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Be · Phase 2 · recruiting
NCT07227012 — Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatmen · Phase 1, PHASE2 · recruiting
NCT06742892 — A Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to · Phase 2 · recruiting
NCT06422403 — A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers · Phase 2 · recruiting
NCT06349980 — A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or W · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01327521 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Albert Koong
Last refreshed: 7 June 2012

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01327521.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing